Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 February 2015Website:
http://rocketpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:50:25 GMTDividend
Analysts recommendations
Institutional Ownership
Similar companies
RCKT Latest News
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
Rocket Pharmaceuticals (RCKT) could experience an increase in value due to increasing confidence in its potential earnings, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. Rocket's pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others.
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia. A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falconi Anemia is expected in the 1st half of 2024. PDUFA date of June 30th of 2024 to determine if Kresladi should be approved for the treatment of patients with leukocyte adhesion deficiency-I.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
Rocket Pharmaceuticals, Inc. stock surged 76% post a "Buy" recommendation, fueled by positive Phase 2 trial news for RP-A501 in Danon disease. RP-A501, targeting a rare disease without current treatments, promises significant market potential, pending trial outcomes and approval. Financial analysis shows Rocket with a strong liquidity position and a 25-month cash runway, despite a notable monthly cash burn.
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
- 1(current)
What type of business is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
What sector is Rocket Pharmaceuticals in?
Rocket Pharmaceuticals is in the Healthcare sector
What industry is Rocket Pharmaceuticals in?
Rocket Pharmaceuticals is in the Biotechnology industry
What country is Rocket Pharmaceuticals from?
Rocket Pharmaceuticals is headquartered in United States
When did Rocket Pharmaceuticals go public?
Rocket Pharmaceuticals initial public offering (IPO) was on 18 February 2015
What is Rocket Pharmaceuticals website?
https://rocketpharma.com
Is Rocket Pharmaceuticals in the S&P 500?
No, Rocket Pharmaceuticals is not included in the S&P 500 index
Is Rocket Pharmaceuticals in the NASDAQ 100?
No, Rocket Pharmaceuticals is not included in the NASDAQ 100 index
Is Rocket Pharmaceuticals in the Dow Jones?
No, Rocket Pharmaceuticals is not included in the Dow Jones index
When does Rocket Pharmaceuticals report earnings?
The next expected earnings date for Rocket Pharmaceuticals is 09 August 2024